Protein & Cell >

2020 , Vol. 11 >Issue 2: 82 - 84

DOI: https://doi.org/10.1007/s13238-019-00673-x

COMMENTARY

Targeting oncogenic SOX2 in human cancer cells: therapeutic application

  • Shizhen Zhang 1,2 ,
  • Yi Sun , 1,2
Expand
  • 1. Division of Radiation and Cancer Biology, Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
  • 2. The Cancer Institute of the Second Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou 310029, China

Published date: 15 Feb 2020

Copyright

2019 The Author(s)
Fold

Cite this article

Shizhen Zhang , Yi Sun . Targeting oncogenic SOX2 in human cancer cells: therapeutic application[J]. Protein & Cell, 2020 , 11(2) : 82 -84 . DOI: 10.1007/s13238-019-00673-x

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
Cui CP, Zhang Y, Wang C, Yuan F, Li H, Yao Y, Chen Y, Li C, Wei W, Liu CH (2018) Dynamic ubiquitylation of Sox2 regulates proteostasis and governs neural progenitor cell differentiation. Nat Commun 9:4648

DOI

2
Feng R, Wen J (2015) Overviewof the rolesof Sox2in stem cell and development. Biol Chem 396:883–891

DOI

3
Huser L, Novak D, Umansky V, Altevogt P, Utikal J (2018) Targeting SOX2 in anticancer therapy. Expert Opin Ther Targets 22:983–991

DOI

4
Liu L, Liu C, Zhang Q, Shen J, Zhang H, Shan J, Duan G, Guo D, Chen X, Cheng J (2016) SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells. Hepatology 64:814–827

DOI

5
Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6:369–381

DOI

6
Novak D, Huser L, Elton JJ, Umansky V, Altevogt P, Utikal J (2019) SOX2 in development and cancer biology. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2019.08.007

DOI

7
Pietrobono S, Morandi A, Gagliardi S, Gerlini G, Borgognoni L, Chiarugi P, Arbiser JL, Stecca B (2016) Down-regulationof SOX2 underlies the inhibitory effects of the triphenylmethane gentian violet on melanoma cell self-renewal and survival. J Investig Dermatol 136:2059–2069

DOI

8
Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP (2012) EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 11:73

DOI

9
Takahashi K, Yamanaka S (2006) Inductionof pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676

DOI

10
Wu Q, Zhang L, Su P, Lei X, Liu X, Wang H, Lu L, Bai Y, Xiong T, Li D (2015) MSX2 mediates entry of human pluripotent stem cells into mesendoderm by simultaneously suppressing SOX2 and activating NODAL signaling. Cell Res 25:1314–1332

DOI

11
Wuebben EL, Rizzino A (2017) The dark side of SOX2: cancer—a comprehensive overview. Oncotarget 8:44917–44943

DOI

12
Yin Y, Xie CM, Li H, Tan M, Chen G, Schiff R, Xiong X, Sun Y (2019) The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells. Proc Natl Acad Sci USA 116:20528–20538

DOI

13
Zhang C, Leng F, Saxena L, Hoang N, Yu J, Alejo S, Lee L,Qi D, Lu F, Sun H (2019) Proteolysis of methylated SOX2 protein is regulatedby L3MBTL3and CRL4(DCAF5) ubiquitin ligase. JBiol Chem 294:476–489

DOI

14
Zhang X, Lu F, Wang J, Yin F, Xu Z, Qi D, Wu X, Cao Y, Liang W, Liu Y (2013) Pluripotent stem cell protein Sox2 confers sensitivity to LSD1 inhibition in cancer cells. Cell Rep 5:445–457

DOI

15
Zhao Y, Morgan MA, Sun Y (2014) Targeting neddylation pathways to inactivate Cullin-RING ligases for anti-cancer therapy. Antioxid Redox Signal 21:2383–2400

DOI

16
Zhou L, Zhang W, Sun Y, Jia L (2018) Protein neddylation and its alterations in human cancers for targeted therapy. Cell Signal 44:92–102

DOI

Options
Outlines

/

〈 〉